MetaVia Earnings Call Transcripts
Fiscal Year 2026
-
DA-1726, a dual GLP-1/glucagon agonist, shows rapid and significant weight and waist reduction with promising metabolic and liver benefits. Upcoming trials aim for higher efficacy and improved tolerability, with key data expected before year-end.
-
Significant progress was reported for two cardiometabolic assets, with DA-1726 showing strong early efficacy in obesity and vanoglipel meeting endpoints in MASH. Upcoming data releases and ongoing phase I titration studies are expected to drive value, supported by a solid cash position and active partnership discussions.
Fiscal Year 2025
-
DA-1726 and DA-1241 are advancing as differentiated therapies for obesity and NASH, with DA-1726 showing promising early efficacy and safety, and DA-1241 positioned for combination strategies. The pipeline is expanding through AI-driven research and new formulations, with a focus on strategic partnerships.
-
Phase I data for DA-1726 showed strong weight loss and safety without titration, with further dose escalation and trials targeting Wegovy dropouts planned. DA-1241 met endpoints in MASH and is positioned for combination therapy, with a biopsy-driven phase IIb next.
-
DA-1241 showed strong phase 2a results in MASH, while DA-1726 demonstrated superior safety and weight loss at a starting dose, with higher dose studies planned this year. Recent $10M financing extends cash runway into 2026 and supports upcoming clinical milestones.